Recent Company News

• 10:05 PM ET Oct 17, 2025
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 02:44 PM ET Oct 17, 2025
  

  StreetAccount Summary: Notable Drug Events expected for the week of 19-Oct

• 01:43 PM ET Oct 17, 2025
  

  UK closes in on drug pricing deal with White House - FT

• 09:05 AM ET Oct 17, 2025
  

  FDA grants orphan drug designation to niraparib for malignant glioma (1611.5000p, -22.5)

• 08:31 AM ET Oct 16, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 07:08 AM ET Oct 17, 2025
  

  ViiV Healthcare announces 96-week data from PASO DOBLE study of Dovato vs Biktarvy in maintaining virological suppression in HIV-1 pts

• 01:35 AM ET Oct 17, 2025
  

  NICE recommends ViiV Healthcare's cabotegravir (Apretude) as an option for pre-exposure prophylaxis (PrEP)

• 05:43 PM ET Oct 16, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:05 AM ET Oct 15, 2025
  

  SCYNEXIS and GSK resolve disagreement related to the restart of the phase 3 Mario study ($0.81, 0.00)